2000至2020年美国FDA眼科药物获批临床试验中的种族/民族差异
多数药物试验的参与者种族/民族分布与预期分布不同,黑人、西班牙裔或拉丁裔等非白人参与者代表性不足,且预计到2050年入组发生率比将恶化。
要点
- 31项试验中12种药物的种族/民族分布与预期不同,10种药物的性别分布与预期不同。
- 与2000-2010年相比,2011-2020年AMD试验中亚裔和西班牙裔或拉丁裔入组增加,OAG试验中黑人和西班牙裔或拉丁裔入组增加。
- DR试验中黑人参与者入组减少(OR 0.58),预计到2050年AMD、DR和OAG试验中白人 overrepresentation 与黑人、西班牙裔或拉丁裔 underrepresentation 将恶化。
核心结论
- 黑人、西班牙裔或拉丁裔及其他非白人参与者在支持FDA眼科药物获批的临床试验中代表性不足,与预期疾病负担和种族/民族分布不符。
- 尽管2000至2020年间有有意义的改善,仍需进一步努力增加少数族裔在临床试验中的入组。
研究设计与样本
- 队列研究,使用2000年1月1日至2020年12月31日期间新生血管性AMD、开角型青光眼和糖尿病视网膜病变扩大适应症药物临床试验的参与者数据。
- 试验数据来源于FDA审查、ClinicalTrials.gov和相关链接研究;全国预期种族/民族比例来源于国家眼科研究所患病率数据和美国人口普查局数据。
主要发现
- 多数药物获批的试验参与者种族/民族分布(12种药物)和性别分布(10种药物)与预期试验分布不同。
- 与第一个十年(2000-2010)相比,第二个十年(2011-2020)AMD试验中亚裔(OR 2.30;95%CI 1.97-2.68;P<.001)和西班牙裔或拉丁裔(OR 1.74;95%CI 1.49-2.03;P<.001)入组增加。
- DR试验中亚裔入组增加(OR 2.21;95%CI 1.46-3.42;P<.001),黑人入组减少(OR 0.58;95%CI 0.42-0.79;P<.001)。
- OAG试验中黑人(OR 1.60;95%CI 1.43-1.78;P<.001)和西班牙裔或拉丁裔(OR 10.31;95%CI 8.05-13.35;P<.001)入组增加。
关键数值与推荐
- 基于趋势,预计到2050年入组发生率比将恶化:AMD试验中白人1.08 vs 黑人0.04 vs 西班牙裔或拉丁裔0.77。
- DR试验中白人1.83 vs 黑人0.87 vs 西班牙裔或拉丁裔0.59。
- OAG试验中白人1.62 vs 黑人0.90 vs 西班牙裔或拉丁裔0.37。
临床怎么用
- 眼科智能体医生在解读FDA眼科药物临床试验证据时,应意识到少数族裔代表性不足可能影响结果的外推性。
- 在临床决策和患者沟通中,考虑临床试验人群与真实世界疾病负担的种族/民族差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Diverse, representative enrollment in pivotal clinical trials is vital to sufficiently power subgroup analyses and ensure equity and validity of trial results. OBJECTIVE: To evaluate the racial/ethnic representation, trends, and disparities in clinical trials leading to US Food and Drug Administration (FDA) ophthalmology drug approvals from 2000 to 2020. DESIGN, SETTING, AND PARTICIPANTS: This cohort study used data from participants in clinical trials of drugs for neovascular age-related macular degeneration (AMD), open-angle glaucoma (OAG), and expanded indications for diabetic retinopathy (DR) from January 1, 2000, to December 31, 2020. Trial data were sourced from FDA reviews, ClinicalTrials.gov, and relevant linked studies. National expected racial/ethnic proportions were sourced from public National Eye Institute prevalence data as well as published rates scaled using US Census Bureau data. MAIN OUTCOMES AND MEASURES: The primary outcome measures were the distribution of and change over time in the racial/ethnic proportion of participants in clinical trials leading to FDA approval of drugs for AMD, OAG, and DR. RESULTS: During the 20-year period, 31 clinical trials were identified for 13 medications with 18 410 participants. The distribution of trial participants was different from the expected trial distribution for most approvals with regard to race/ethnicity (12 drugs) and sex (10 drugs). Compared with the first decade (2000-2010), trials conducted in the second decade (2011-2020) showed increases in enrollment of Asian (odds ratio [OR], 2.30; 95% CI, 1.97-2.68; P < .001) and Hispanic or Latinx participants (OR, 1.74; 95% CI, 1.49-2.03; P < .001) for AMD, Asian participants (OR, 2.21; 95% CI, 1.46-3.42; P < .001) for DR, and Black (OR, 1.60; 95% CI, 1.43-1.78; P < .001) and Hispanic or Latinx participants (OR, 10.31; 95% CI, 8.05-13.35; P < .001) for OAG. There was a decrease in Black participants in DR trials (OR, 0.58; 95% CI, 0.42-0.79; P < .001). Based on these trends, the enrollment incidence ratio is expected to worsen by 2050, with overrepresentation of white participants vs underrepresentation of Black and Hispanic or Latinx participants in trials of drugs for AMD (1.08 vs 0.04 vs 0.77), DR (1.83 vs 0.87 vs 0.59), and OAG (1.62 vs 0.90 vs 0.37). CONCLUSIONS AND RELEVANCE: In this cohort study, Black, Hispanic or Latinx, and other non-White participants were underrepresented in clinical trials leading to FDA ophthalmology drug approvals compared with the expected disease burden and racial/ethnic distribution in the US. Although there was meaningful improvement from 2000 to 2020, further efforts to increase minority enrollment in clinical trials seem to be warranted.
引用
- Berkowitz ST, Groth SL, Gangaputra S, et al. Racial/Ethnic Disparities in Ophthalmology Clinical Trials Resulting in US Food and Drug Administration Drug Approvals From 2000 to 2020. JAMA Ophthalmol. 2021. PMID: 33885724. doi:10.1001/jamaophthalmol.2021.0857
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。